轩竹生物再报考港交所上市，多个项目已获批准

Core Viewpoint - Xuanzhu Biopharmaceutical Co., Ltd. has submitted a new prospectus for an IPO on the Hong Kong Stock Exchange after previously withdrawing its application for listing on the Shanghai Stock Exchange due to strategic considerations and market conditions [1][3]. Company Overview - Xuanzhu Biopharmaceutical was established in September 2018 and is located in Shijiazhuang, Hebei Province. The company focuses on developing innovative drugs for major diseases such as digestive disorders, cancer, and non-alcoholic fatty liver disease (NASH) [3][5]. - The company has a registered capital of approximately 450 million RMB and is primarily owned by Sihuan Pharmaceutical, among other shareholders [3]. Financial Performance - The company reported revenues of approximately 29,000 RMB, 30.09 million RMB, and 2.56 million RMB for the years 2023, 2024, and the first quarter of 2025, respectively. Other income and gains were approximately 40.8 million RMB, 15.35 million RMB, and 1.55 million RMB for the same periods [5][6]. - Xuanzhu Biopharmaceutical has incurred significant losses, with pre-tax losses of approximately 300.56 million RMB, 556.42 million RMB, and 65.46 million RMB for the years 2023, 2024, and the first quarter of 2025, respectively [6]. Product Pipeline - The company is actively developing over 10 drug assets targeting digestive system diseases, cancer, and NASH. This includes two assets in the NDA approval stage and four projects in Phase I clinical trials [5]. - Three core products include KBP-3571 (an innovative proton pump inhibitor for digestive diseases), XZP-3287 (a CDK4/6 inhibitor targeting breast cancer), and XZP-3621 (an ALK inhibitor for non-small cell lung cancer) [5].